Besides inhibiting the EGFR pathway, anti-EGFR mAbs may exert anti-tumour effects through ADCC (110). This is the case of cetuximab, a chimeric IgG1 mAb directed to the extracellular domain of the EGFR, which has been approved to treat KRAS wild-type metastatic CRC (mCRC) (111) and HNSCC (112). The gene discussed is EGFR; the disease is neoplasm.